In this article, we will take a look at the 12 stocks that will double in 2025.

Mutual Advisors LLC bought a new position in ImmunityBio, Inc. (NASDAQ:IBRX – Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC).

ImmunityBio shares were up 14% to $3.52 after the company entered into a collaboration and supply agreement with BeiGene. The two companies will conduct a confirmatory randomized Phase 3 clinical ...

Starbucks Corporation SBUX gained 5.7% to $106.15 following better-than-expected quarterly financial results. Additionally, ...

Trump’s attempt to block previously approved Congressional funding not only threatens social programs that benefit millions, ...

The market remained flat over the last week but is up 23% over the past year, with earnings forecast to grow by 15% annually. In this context, identifying high growth tech stocks involves looking for ...

ImmunityBio (IBRX) announced the European Medicines Agency has accepted for review and begun assessing the marketing authorization application ...

2025 is set to be a game-changing year for cancer research, with cutting-edge therapies and technologies driving unprecedented progress in oncology.

ImmunityBio has a promising cancer treatment, Anktiva. We warn of financial risks and lack of transparency for retail investors. See more on IBRX stock here.

We recently compiled a list of the 12 Stocks Under $5 With Biggest Upside Potential. In this article, we are going to take a ...

D. Boral Capital reiterated their buy rating on shares of ImmunityBio (NASDAQ:IBRX – Free Report) in a research report sent to investors on Thursday morning,Benzinga reports. D. Boral Capital ...

We recently compiled a list of the These 10 Firms Dominated Last Week's Rally. In this article, we are going to take a look ...